Be the first to review this item
Heart Support during workout
Riboxin (Riboxinum). 9-b -D- Ribofuranozilgipoksantin or gipoksantin- ribozid.
Synonyms : Inozie-F, Inozin, Atorel, Inosie-F, Inosin, Inosiron-E, Inotin, Irpelen, Oxiamin, Ribonosine, Teberin, Trophicardyl and others.
Riboxin is derived (nukleozidom) Purina. It can be viewed as a predecessor ATF. There is evidence of the ability of drugs to enhance the activity of some enzymes Krebs cycle, stimulate the synthesis of nucleotides, have positive effects on the metabolic processes in the attack and improve coronary circulation. By type of action related to anabolic substances. As nukleozidom, inozin can penetrate into cells and increase energy balance attack.
Riboxin applied to the treatment of coronary heart disease, myocardial infarction forward, myocardiodystrophy, rhythm irregularities involving the use of cardiac glycosides. Assign well as liver diseases (hepatitis, cirrhosis), and for the treatment urokoproporfirii. There is also an improvement by riboksina visual function in patients with glaucoma (otkrytougolnaya form with an under the influence of anti-hypertensive therapy inner pressure). The effect apparently associated with antihypoxic of preparation.
When maximum stimulation is reached, inosine is converted into nutrients used by the body. A daily supplement of inositol provides this supplement in purity and potency, and is recommended for daily use.
Indications for use:
Applied also riboxin intravenously. Enter slow drip (40-60 drops per minute). Beginning with the treatment of 200 mg (10 ml of 2% solution) 1 times a day, then, with good endurance, increase the dose to 400 mg (20 ml of 2% solution) 1 to 2 times a day. The duration of treatment of 10 to 15 days.
In severe violations of heart rhythm and conduction may inkjet products in a single dose of 200 to 400 mg (10 to 20 ml of 2% solution).
Important notice- the outer box design may vary before prior notice!
Someone from the Denmark - just purchased the goods:
Genferon 1 000 000 ME 10 pieces